Fool.com
The World's Greatest Investing Community
Results 51 - 60 of 513 : Previous 2 3 4 5 6 7 8 9 10 Next
Here We Go Again With Possible Side Effects
Merck is the newest victim.
These are the right stocks for your retirement accounts.
Solid data. Now let's see how phase 3 turns out.
Alkermes Needs Some Financial Alchemy
After a string of research and marketing disappointments, the company's CEO departs.
Pfizer and Wyeth Put the Horse Before the Cart
The pharmas' animal-business divestiture brings them one step closer to unity.
3 Ridiculously Cheap, High-Quality Companies
Come get 'em while they're hot.
Companies That Will Thrive Under Obamacare
They are out there.
It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it.
Double Your Dividends in 6 Years
Here's how you can collect thousands of dollars yearly (and easily).
More Tests for Drug for Cancer Patients
A combination doesn't work, but two companies will keep trying.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK